Know Cancer

forgot password

Combination Chemotherapy With or Without Maintenance Sunitinib Malate (IND 74019; NSC 736511) For Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study

Phase 1/Phase 2
18 Years
Open (Enrolling)
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer

Thank you

Trial Information

Combination Chemotherapy With or Without Maintenance Sunitinib Malate (IND 74019; NSC 736511) For Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study


I. To determine the phase II dose for sunitinib combined with cisplatin and etoposide.

II. Phase II: To compare the progression-free survival of patients with extensive stage
small cell lung cancer treated with cisplatin or carboplatin and etoposide followed by
maintenance sunitinib to patients receiving the same chemotherapy followed by placebo.


I. To assess the single agent response rate for sunitinib given as monotherapy after

II. To assess the overall survival of patients treated with cisplatin or carboplatin and
etoposide followed by sunitinib.

III. To evaluate the toxicity and tolerability of maintenance sunitinib after cisplatin or
carboplatin and etoposide.

IV. To determine the association between VEGF plasma levels and tumor response.

OUTLINE: This is a phase I, dose-escalation study of sunitinib malate followed by a phase II
study. Patients are stratified according to treatment (cisplatin vs carboplatin), and
courses (< 6 courses vs 6 courses).

PHASE I: (close to accrual 5/17/08) Combination chemotherapy: Patients receive cisplatin or
carboplatin intravenously (IV) on day 1, etoposide IV on days 1-3, and sunitinib malate
orally (PO) once daily on days 1-14.

Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or
unacceptable toxicity. Cohorts of 6 patients receive escalating doses of sunitinib malate
until the recommended phase II dose is determined. The recommended phase II dose is the dose
preceding that at which 2 of 6 patients experience dose-limiting toxicity.

MAINTENANCE THERAPY: Patients receive sunitinib malate PO alone once daily. Treatment
continues in the absence of disease progression or unacceptable toxicity.

PHASE II: Combination chemotherapy: Patients receive cisplatin or carboplatin and etoposide
as in phase I.

Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or
unacceptable toxicity.

MAINTENANCE THERAPY: Beginning 3-8 weeks after completion of combination chemotherapy or ≥ 4
courses of combination therapy, patients with a responding or stable disease are randomized
to 1 of 2 treatment arms. All patients must be euthyroid before starting on maintenance

ARM I: Patients receive sunitinib malate PO once daily.

Treatment repeats every 3 weeks in the absence of disease progression or unacceptable

ARM II: Patients receive placebo PO once daily.

Treatment repeats every 3 weeks in the absence of disease progression or unacceptable
toxicity. Patients with disease progression may cross over to Arm I.

After completion of study treatment, patients are followed every 3 months for 1 year and
then every 6 months for 2 years.

Inclusion Criteria:

- Histologically or cytologically confirmed small cell lung cancer

- Extensive-stage disease, defined as any of the following:

- Extrathoracic metastases

- Malignant pleural effusion

- Bilateral or contralateral supraclavicular adenopathy or contralateral
hilar adenopathy

- No limited-stage disease, defined as disease restricted to 1 hemithorax with
regional lymph node metastases, including hilar, ipsilateral and contralateral
mediastinal, and/or ipsilateral supraclavicular nodes

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR ≥ 10 mm by spiral CT scan

- No nonmeasurable disease, including all of the following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural or pericardial effusion

- Lymphangitis cutis/pulmonis

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- No history of spinal cord compression or carcinomatous meningitis

- No history of brain metastases

- CTC performance status 0-1 (phase I) OR 0-2 (phase II)

- Absolute granulocyte count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Creatinine clearance ≥ 70 mL/min

- Bilirubin ≤ 1.5 mg/dL

- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for patients with
liver metastases)

- PTT ≤ 1.5 ULN

- Not pregnant or nursing

- No current active second malignancy other than non-melanoma skin cancers

- No ongoing cardiac dysrhythmias or atrial fibrillation

- QTc interval < 500 msec

- No New York Heart Association (NYHA) class III-IV heart failure within the past 12

- NYHA class II heart failure allowed, provided all of the following criteria are

- Asymptomatic on treatment

- Prior anthracycline exposure

- Received prior central thoracic radiotherapy that included the heart in the
radiotherapy port

- None of the following within the past year:

- Myocardial infarction

- Coronary or peripheral artery bypass graft or stenting

- Severe or unstable angina

- Cerebrovascular accident, including transient ischemic attack

- Pulmonary embolism

- No hypertension that cannot be controlled by medications (i.e., blood pressure >
150/100 mm Hg despite optimal medical therapy)

- No hemoptysis within the past 4 weeks

- Patients with blood-tinged or blood-streaked sputum are eligible if < 5 mL of
blood per episode and < 10 mL of blood/24 hours

- None of the following within the past 28 days:

- Abdominal fistula

- Gastrointestinal perforation

- Intra-abdominal abscess

- Serious or nonhealing wound

- Ulcer

- Bone fracture

- No prior chemotherapy for small cell lung cancer

- At least 1 week since prior radiotherapy

- At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the

- Azole antifungals (e.g., ketoconazole, itraconazole)

- Diltiazem

- Clarithromycin

- Erythromycin

- Verapamil

- Delavirdine

- HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir,

- At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the

- Rifampin

- Rifabutin

- Carbamazepine

- Phenobarbital

- Phenytoin

- Hypericum perforatum (St. John's wort)

- Efavirenz

- Tipranavir

- No concurrent therapeutic doses of coumarin-derivative anticoagulants

- Doses ≤ 2 mg daily for prophylaxis of thrombosis allowed

- Concurrent low molecular weight heparin allowed provided PT INR ≤ 1.5

- No other concurrent chemotherapy

- No concurrent hormonal therapy

- Concurrent steroids for adrenal failure, hormones for non-disease-related
conditions (e.g., insulin for diabetes), or intermittent dexamethasone allowed

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Highest safe dose of sunitinib malate in combination with cisplatin and etoposide (Phase I)

Outcome Time Frame:

Up to 21 days of course 1

Safety Issue:


Principal Investigator

Neal Ready

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer and Leukemia Group B


United States: Food and Drug Administration

Study ID:




Start Date:

March 2007

Completion Date:

Related Keywords:

  • Extensive Stage Small Cell Lung Cancer
  • Recurrent Small Cell Lung Cancer
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Memorial Sloan Kettering Cancer Center New York, New York  10021
Washington University School of Medicine Saint Louis, Missouri  63110
Rhode Island Hospital Providence, Rhode Island  02903
Methodist Medical Center of Illinois Peoria, Illinois  61636
Memorial Hospital of South Bend South Bend, Indiana  46601
Eastern Maine Medical Center Bangor, Maine  04401
Peninsula Regional Medical Center Salisbury, Maryland  21801
Saint Anthony Medical Center Rockford, Illinois  61108
Methodist Estabrook Cancer Center Omaha, Nebraska  68114-4199
Elkhart General Hospital Elkhart, Indiana  46515
South Bend Clinic South Bend, Indiana  46617
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio  43210-1240
Alta Bates Summit Medical Center - Summit Campus Oakland, California  94609
Beebe Medical Center Lewes, Delaware  19958
Memorial Hospital Carthage, Illinois  62321
Galesburg Cottage Hospital Galesburg, Illinois  61401
Galesburg Clinic Galesburg, Illinois  61401
Mason District Hospital Havana, Illinois  62644
Kewanee Hospital Kewanee, Illinois  61443
McDonough District Hospital Macomb, Illinois  61455
BroMenn Regional Medical Center Normal, Illinois  61761
Proctor Hospital Peoria, Illinois  61614
Perry Memorial Hospital Princeton, Illinois  61356
Creighton University Medical Center Omaha, Nebraska  68131-2197
Iredell Memorial Hospital Statesville, North Carolina  28677
Mountainview Medical Berlin, Vermont  05602
Danville Regional Medical Center Danville, Virginia  24541
Eureka Hospital Eureka, Illinois  61530
Graham Hospital Association Canton, Illinois  61520
Holy Family Medical Center Des Plaines, Illinois  60016
Saint Joseph Medical Center Joliet, Illinois  60435
Pekin Hospital Pekin, Illinois  61554
Highland General Hospital Oakland, California  94602
Union Hospital of Cecil County Elkton MD, Maryland  21921
Miriam Hospital Providence, Rhode Island  02906
McLeod Regional Medical Center Florence, South Carolina  29501
La Grange Memorial Hospital La Grange, Illinois  60525
Duke University Medical Center Durham, North Carolina  27710
East Bay Radiation Oncology Center Castro Valley, California  94546
Contra Costa Regional Medical Center Martinez, California  94553-3156
Larry G Strieff MD Medical Corporation Oakland, California  94609
Glens Falls Hospital Glens Falls, New York  12801
Holy Cross Hospital Fort Lauderdale, Florida  33308
El Camino Hospital Mountain View, California  94040
New Hampshire Oncology-Hematology PA Hooksett, New Hampshire  03106
University Of Vermont Burlington,, Vermont  05403
Alegent Health Immanuel Medical Center Omaha, Nebraska  68122
Alegent Health Bergan Mercy Medical Center Omaha, Nebraska  68124
Addison Gilbert Hospital Gloucester, Massachusetts  01930
Virginia Commonwealth University Richmond, Virginia  
Memorial Health University Medical Center Savannah, Georgia  31404
University of Chicago Comprehensive Cancer Center Chicago, Illinois  60637-1470
Northern Indiana Cancer Research Consortium South Bend, Indiana  
Wake Forest University Health Sciences Winston-Salem, North Carolina  27157
OSF Saint Francis Medical Center Peoria, Illinois  61637
Valley Medical Oncology Consultants-Castro Valley Castro Valley, California  94546
Valley Medical Oncology Consultants-Fremont Fremont, California  94538
Bay Area Breast Surgeons Inc Oakland, California  94609
Bay Area Tumor Institution CCOP Oakland, California  94609
Tom K Lee Inc Oakland, California  94609
Doctors Medical Center- JC Robinson Regional Cancer Center San Pablo, California  94806
Lombardi Comprehensive Cancer Center at Georgetown University Washington, District of Columbia  20057
Hopedale Medical Complex - Hospital Hopedale, Illinois  61747
Community Cancer Center Foundation Normal, Illinois  61761
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois  61350
Ottawa Regional Hospital and Healthcare Center Ottawa, Illinois  61350
Pekin Cancer Treatment Center Pekin, Illinois  61554
Illinois Oncology Research Association CCOP Peoria, Illinois  61615
Illinois CancerCare-Peoria Peoria, Illinois  61615
Illinois Valley Hospital Peru, Illinois  61354
Saint Margaret's Hospital Spring Valley, Illinois  61362
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Fort Wayne, Indiana  46845
Lakeland Hospital St. Joseph, Michigan  49085
Minneapolis Veterans Medical Center Minneapolis, Minnesota  55417
Lincoln Medical Education Foundation Cancer Resource Center Lincoln, Nebraska  68510
Missouri Valley Cancer Consortium CCOP Omaha, Nebraska  68106
New Hampshire Oncology Hematology Associates Hooksett, New Hampshire  03106
LRGHealthcare-Lakes Region General Hospital Laconia, New Hampshire  03246
Cooper Hospital University Medical Center Camden, New Jersey  08103
State University of New York Upstate Medical University Syracuse, New York  13210
Wayne Memorial Hospital Goldsboro, North Carolina  27534
Margaret R Pardee Memorial Hospital Hendersonville, North Carolina  28791
University of Maryland Greenebaum Cancer Center Baltimore, Maryland  21201
Jupiter Medical Center Jupiter, Florida  33458
Gainesville Hematology Oncology Associates Gainesville, Florida  32605
Elkhart Clinic Elkhart, Indiana  46515
Mount Sinai Medical Center CCOP Miami Beach, Florida  33140
Illinois CancerCare-Bloomington Bloomington%, Illinois  61701
Illinois CancerCare-Canton Canton, Illinois  61520
Illinois CancerCare-Carthage Carthage, Illinois  62321
Illinois CancerCare-Eureka Eureka, Illinois  61530
Illinois CancerCare-Havana Havana, Illinois  62644
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois  61443
Illinois CancerCare-Macomb Macomb, Illinois  61455
Illinois CancerCare-Monmouth Monmouth, Illinois  61462
Illinois CancerCare-Community Cancer Center Normal, Illinois  61761
Illinois CancerCare-Pekin Pekin, Illinois  61603
Illinois CancerCare-Peru Peru, Illinois  61354
Illinois CancerCare-Princeton Princeton, Illinois  61356
Illinois CancerCare-Spring Valley Spring Valley, Illinois  61362
Michiana Hematology Oncology PC-Elkhart Elkhart, Indiana  46514
Michiana Hematology Oncology PC-Plymouth Plymouth, Indiana  46563
Michiana Hematology Oncology PC-South Bend South Bend, Indiana  46601
Michiana Hematology Oncology-PC Westville Westville, Indiana  46391
Michiana Hematology Oncology PC-Niles Niles, Michigan  49120
University of Missouri - Ellis Fischel Columbia, Missouri  65203
University of Minnesota Medical Center-Fairview Minneapolis, Minnesota  55455
FirstHealth of the Carolinas-Moore Regional Hosiptal Pinehurst, North Carolina  28374
Palchak David MD Pismo Beach, California  93449
Beaufort Memorial Hospital Beaufort, South Carolina  29902
Michiana Hematology Oncology PC-Mishawaka Mishawaka, Indiana  46545-1470
Marie Yeager Cancer Center Saint Joseph, Michigan  49085
Hematology Oncology Associates of Central New York PC East Syracuse, New York  13057
Community Howard Regional Health Kokomo, Indiana  46904
Indiana University Health La Porte Hospital La Porte, Indiana  46350
Saint Joseph Regional Medical Center-Mishawaka Mishawaka, Indiana  46545-1470
Christiana Care Health System-Christiana Hospital Newark, Delaware  19718